European MidPharmas are a class of companies that Novasecta has been specialising in since its foundation. These R&D-based pharmaceutical companies with annual revenues of €50m to €5bn are tremendously diverse, just like the European countries in which they are based. Working closely with these companies for over a decade has provided us with a substantial body of insight into how these companies and their larger and smaller competitors can sustainably grow and improve performance.
What our clients
say about us
We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.Kjetil Hestdal